Skip to main content
. Author manuscript; available in PMC: 2017 Aug 15.
Published in final edited form as: Eur J Pharmacol. 2015 Nov 3;785:144–155. doi: 10.1016/j.ejphar.2015.11.001

Fig. 4.

Fig. 4

Cellular targets and receptors for resolvins, protectins, and maresins. SPMs signal through specific 7-transmembrane G-protein coupled receptors. Lipoxin A4 (LXA4) and the D-series resolvins, in particular RvD1 are agonists for the ALX/FPR2 receptor that is present on a wide variety of leukocytes and other cells. RvE1 and RvE2 are agonists for the CMKLR1/ERV receptor, which is widely expressed on immune cells, and antagonists at the BLT1 receptor. The D-series resolvins are also agonists at the DRV1 and DRV2 receptors. The receptors for protectins and maresins have yet to be molecularly characterized. SPMs signal through these specific receptors to exert influence on leukocytes including halting neutrophil trafficking, promoting macrophage phagocytosis of apoptotic cells and microbes, and blocking further pro-inflammatory cytokine and chemokine production.